SLC5A2 and myocardial infarction: Other differences in the EMPRESS‐MI inclusion criteria will provide new data on the safety of initiation of an SGLT2 inhibitor following acute MI in patients with lower systolic blood pressure (>90 mmHg) and eGFR (>30 mL/min/1.73 m2) than in EMMY (blood pressure ≥100/70 mmHg and eGFR >45 mL/min/1.73 m2).